Fig. 1From: Clinical and genetic risk factors for Fulvestrant treatment in post-menopause ER-positive advanced breast cancer patientsKaplan–Meier curves for progression-free survival probabilities for all enrolled 136 patients (a) and stratified by Fulvestrant lines (b)Back to article page